Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06920290 · ClinicalTrials.gov registry record
Visual Field Analysis With Artificial Intelligence
A clinical trial of Glaucoma and Visual Field Defect, sponsored by Sight Intelligence Engineering Corporation.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06920290: Active study of Glaucoma and Visual Field Defect, sponsored by Sight Intelligence Engineering Corporation.
NCT06920290 is a study of Glaucoma and Visual Field Defect that is active but no longer recruiting, run by Sight Intelligence Engineering Corporation. The registered enrollment target is 100 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06920290, a study of Glaucoma and Visual Field Defect, is active but no longer recruiting, sponsored by Sight Intelligence Engineering Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to analyze visual field data from healthy participants. This data will be used to develop and optimize a new visual field perimeter test. The test will incorporate an advanced algorithm, which may include the use of Artificial Intelligence (AI), to enhance accuracy and efficiency in identifying test points.
Primary Outcome
At each position of the peripheral visual field, a healthy individual's ability to see a test point will be measured. The brightness (measured in apostilbs) along a logarithmic scale (0.1 dB to 1000 dB) will be adjusted and the threshold will be defined as a brightness at which the healthy individual can see that test point \> 50% of the time.
Conditions Studied
Interventions
- DEVICE Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence
Study Locations (1)
Virginia
- Sight Intelligence Engineering - Alexandria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2026-08-31 |
What the registry record for NCT06920290 still lists
NCT06920290 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence is the first listed.
NCT06920290 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06920290 about?
NCT06920290 is a clinical study titled "Visual Field Analysis With Artificial Intelligence". The purpose of this study is to analyze visual field data from healthy participants. This data will be used to develop and optimize a new visual field perimeter test. The test will incorporate an advanced algorithm, which may include the use of Artificial Intelligence (AI), to enhance accuracy and e...
What is the current status of trial NCT06920290?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2025-07-01. Estimated completion is 2026-08-31.
What conditions does trial NCT06920290 study?
This clinical trial studies the following conditions: Glaucoma, Visual Field Defect.
What interventions are being tested in trial NCT06920290?
The interventions under investigation include: Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence (DEVICE).
Who is sponsoring clinical trial NCT06920290?
This trial is sponsored by Sight Intelligence Engineering Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06920290 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06920290's enrollment target sits among peer trials
100 44th of 92 higher than 48 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Eye Pressure Lowering Surgery
RECRUITING
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI